Abstract
Eradication rates of triple therapy--a proton pump inhibitor, clarithromycin and amoxicillin twice daily for 7 days--are suboptimal in some areas of the world. Triple therapy combining ranitidine-bismuth citrate, tetracycline and metronidazole is a very effective second-line therapy. Management strategies including this treatment as first-line therapy may represent a reasonable choice. To evaluate the efficacy of a strategy combining ranitidine-bismuth citrate triple therapy followed by a proton pump inhibitor-based triple therapy for Helicobacter pylori eradication in a pilot study. One hundred and thirty-six consecutive H. pylori-positive patients were treated with 400 mg ranitidine-bismuth citrate twice daily, 500 mg tetracycline three times daily and 500 mg metronidazole three times daily for 7 days. Second-line therapy consisted of 20 mg omeprazole twice daily, 500 mg clarithromycin twice daily and 1 g amoxicillin twice daily for 7 days. The efficacy of the treatment was evaluated by histology or the urea breath test. Cure rates were 109/136 patients [80.2%; 95% confidence interval (CI), 72-86%] by intention to treat and 109/127 (85.8%; 95% CI, 78-91%) per protocol. Fifteen of the patients with treatment failure received s...Continue Reading
References
Apr 1, 1997·Gut·J E Domínguez-MuñozP Malfertheiner
Jan 23, 1999·Gut·X Calvet, R Comet
Oct 30, 1999·Alimentary Pharmacology & Therapeutics·J P GisbertJ M Pajares
Jan 5, 2000·BMJ : British Medical Journal·W A de Boer, G N Tytgat
Jan 13, 2000·Alimentary Pharmacology & Therapeutics·A GasbarriniG Gasbarrini
Mar 30, 2000·Medicina clínica·J P GisbertR Sáinz
Jun 10, 2000·Medicina clínica·F BañosR Morera
Aug 23, 2000·Medicina clínica·F GomollónM A Simón
Jun 26, 2001·Alimentary Pharmacology & Therapeutics·X CalvetI Sanfeliu
Feb 28, 2002·Alimentary Pharmacology & Therapeutics·P MalfertheinerUNKNOWN European Helicobacter Pylori Study Group (EHPSG)
May 9, 2002·Enfermedades infecciosas y microbiología clínica·Eva Cuchí BurgosJavier Garau Alemany
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·X CalvetUNKNOWN Group for Eradication Studies from Catalonia and Aragón (Gresca)
Nov 20, 2002·European Journal of Gastroenterology & Hepatology·Gerassimos J MantzarisGeorge Triantafyllou
Nov 28, 2002·Gastroenterology·Peter H KatelarisBrendan Crotty
Feb 4, 2003·Alimentary Pharmacology & Therapeutics·C O'MorainUNKNOWN International multicentre study
Mar 26, 2003·The American Journal of Gastroenterology·Loren LaineJean Spénard
May 20, 2003·Alimentary Pharmacology & Therapeutics·E GenéJ P Gisbert
Citations
Feb 25, 2005·Current Infectious Disease Reports·Francis Mégraud
Jun 15, 2007·Journal of Gastroenterology and Hepatology·Ahmet UygunOmer Gunhan
May 21, 2005·Helicobacter·Javier P GisbertXavier Calvet
Sep 24, 2005·Helicobacter·Peter Bytzer, Colm O'Morain
Apr 18, 2018·Helicobacter·Neus MuñozXavier Calvet